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Deep brain electrical 
neurofeedback allows Parkinson 
patients to control pathological 
oscillations and quicken 
movements
Oliver Bichsel1,2,3,4*, Lennart H. Stieglitz3,4, Markus F. Oertel3,4, Christian R. Baumann2,4, 
Roger Gassert1,6 & Lukas L. Imbach2,4,5,6 
Parkinsonian motor symptoms are linked to pathologically increased beta-oscillations in the 
basal ganglia. While pharmacological treatment and deep brain stimulation (DBS) reduce these 
pathological oscillations concomitantly with improving motor performance, we set out to explore 
neurofeedback as an endogenous modulatory method. We implemented real-time processing of 
pathological subthalamic beta oscillations through implanted DBS electrodes to provide deep brain 
electrical neurofeedback. Patients volitionally controlled ongoing beta-oscillatory activity by visual 
neurofeedback within minutes of training. During a single one-hour training session, the reduction of 
beta-oscillatory activity became gradually stronger and we observed improved motor performance. 
Lastly, endogenous control over deep brain activity was possible even after removing visual 
neurofeedback, suggesting that neurofeedback-acquired strategies were retained in the short-term. 
Moreover, we observed motor improvement when the learnt mental strategies were applied 2 days 
later without neurofeedback. Further training of deep brain neurofeedback might provide therapeutic 
benefits for Parkinson patients by improving symptom control using strategies optimized through 
neurofeedback.
Patients with Parkinson’s disease (PD) suffer from progressive impairment of motor function caused by a loss of 
dopaminergic neurones in the basal ganglia and  brainstem1. Symptomatic treatments of PD include dopaminergic 
drugs or deep brain stimulation (DBS). In DBS, electrodes are implanted into basal ganglia nuclei—typically 
the subthalamic nucleus (STN) or the globus pallidus internus (GPi)—both of which are relevant structures in 
affected movement modulatory  circuits2. Besides greatly and almost immediately alleviating motor symptoms 
through the application of high frequency stimulation, implanted DBS electrodes have also shed light on the 
electrophysiological hallmarks of PD through recording of deep brain local field potentials (LFP).
Characteristically, patients with PD show pathologically increased levels of beta-oscillatory  activity3–5. Beta-
oscillations have been correlated with clinical measures of PD, with a reduction of signal power in the beta-band 
corresponding to a clinical improvement of motor  symptoms6–8. Furthermore, the two main therapeutic strate-
gies, the administration of l-Dopa3,9 and high-frequency  DBS8,10, both lead to a suppression of beta-synchronicity 
in the STN. Beta-oscillations show fast and movement-dependent modulation over  time11,12 and have been 
proposed as a feedback signal to control the delivery of DBS in a closed-loop  system13.
Besides the exogenous manipulation of subthalamic oscillatory activity through pharmacotherapy and DBS, 
it remains to be unveiled whether endogenous modulation is also achievable. Neurofeedback has emerged as 
a promising, endogenous technique enabling self-regulation of ongoing brain activity. It relies on the real-
time extraction of relevant features from neuronal activity, that is presented to the subject. Such a real-time 
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self-modulation would be especially useful in sudden exacerbations of symptoms, which are characteristic for 
PD. Cortical modulation of oscillations through electrical neurofeedback has already been shown successful in a 
sample of three PD patients controlling beta-band power from sensorimotor  areas14, as well as in three macaques 
where the downregulation of cortical beta-activity resulted in significantly faster movement  onsets15.
The modulation of deep brain activity through neurofeedback is not a new notion per se and has been explored 
by a large body of real-time functional magnetic resonance imaging (rtfMRI) research, providing for instance evi-
dence for voluntary control over the substantia nigra/ventral tegmental area complex (SN/VTA) through mental 
 imagery16. However, compared to LFP recordings, rtfMRI is confined to the laboratory environment, suffers from 
a time lag of several seconds caused by the haemodynamic response and is limited by a low temporal resolution 
of typically 1–2 s. Using LFP recordings from DBS electrodes, a recent study showed that the 5 min average 
resting subthalamic beta-activity could be voluntarily controlled in the instructed direction through 10 min 
of  neurofeedback17. Nevertheless, it remains to be unveiled whether deep brain electrode-guided neurofeed-
back allows for instantaneous modulation of ongoing subcortical activity as well as whether modulatory effects 
improve with exposure time, are maintained after removal of neurofeedback and reduce motor impairment.
We hypothesise that through electrical deep brain neurofeedback, PD patients can learn to volitionally control 
the amount of pathological subthalamic beta-oscillations in real-time and thereby reduce motor impairment. 
Ultimately, endogenously modulating pathological deep brain oscillations could serve as a new approach to 
reduce Parkinsonian motor symptoms.
Materials and methods
Study cohort and surgery. We included ten PD patients (Table 1) undergoing bilateral DBS lead (Model 
3389, Medtronic Neurological Division, Minneapolis, MN, USA) implantation into the STN. DBS leads were 
implanted after MRI-based direct targeting of the STN. Accurate implantation within the STN was intraopera-
tively verified by micro-electrode recordings (Leadpoint, Medtronic Neurological Division, Minneapolis, MN, 
USA) in steps of 0.5 mm until the pars reticulata of the substantia nigra (starting 10 mm above the target), as well 
as clinical response upon intraoperative stimulation and intraoperative computed tomography (CT). We verified 
accurate electrode placement by comparing the planned and actual electrode position in the postoperative CT 
scan. As commonly performed at our institution, the internalisation and connection of the leads to the stimula-
tion device (Activa PC, Medtronic Neurological Division, Minneapolis, MN, USA) was performed 3–5 days 
after the first surgery (two-stage surgical approach). All experiments were performed with externalised DBS 
leads on the second postoperative day in l-Dopa OFF as well as DBS OFF state and prior to the second stage of 
surgery. Decisions on patient selection and surgical procedures were not affected by this study and exclusively 
based on clinical grounds. This study was approved by the local ethics committee (Kantonale Ethikkommission 
Zürich, board decision on the amendment to KEK-ZH: 2012–0327), and all patients gave informed written 
consent prior to inclusion.
Experimental setup. We measured STN LFPs from temporarily externalised DBS wires (4 electrode sites 
per lead) sampled at 5 kHz by a BrainAmp DC (Brain Products GmbH, Gilching, Germany) EEG recorder. A 
ground and a reference scalp EEG input were placed over the central midline region  Cz (according to the inter-
national 10/20 system) and connected to the EEG recorder. All electrode impedances were < 5 kOhm and signal 
quality was checked visually for electrode or movement artefacts. All experiments were performed in a sitting or 
supine position such that patients were able to see the computer screen providing visual feedback. As a baseline 
Table 1.  Demographics and clinical patient characteristics. The third part of the MDS-UPDRS includes the 
clinician-scored, monitored motor evaluation (33 scores based on 18 items)19, ranging from the worst MDS-
UPDRS III score of 132 (= 4.33) points to 0 points (as in healthy individuals). The minimal clinically important 
difference on the UPDRS motor score is 2.3–2.7  points20. For patients 1, 8 and 10, the PD-dominant hand was 
the left hand, while for all others the PD-dominant hand was the right hand. MDS-UPDRS Movement Disorder 
Society-Unified Parkinson’s Disease Rating Scale, ON/OFF values of preoperative l-Dopa challenge test, LED 
preoperative levodopa equivalent  dose18.










1 70 M Equivalent Left 10 2.5 37/62 2340
2 63 M Akinetic-rigid Right 7 2.5 27/44 1800
3 45 M Tremor Right 2 1.5 19/28 375
4 60 M Tremor Right 19 1.5 17/41 1750
5 62 F Akinetic-rigid Right 10 2.5 29/46 275
6 65 M Equivalent Right 9 2 20/32 1240
7 57 F Equivalent Right 9 2 25/54 620
8 71 M Tremor Left 4 2.5 19/35 1350
9 58 F Equivalent Right 13 2.5 20/33 1500
10 48 M Equivalent Left 5 2 24/43 1525
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condition, we first recorded a resting state condition in which patients looked at a blacked monitor for 60 s. 
Using the BrainVision Recorder and Analyzer (both from BrainProducts GmbH, Gilching, Germany), we then 
identified the pair of adjacent electrode contacts in the STN contralateral to the PD-dominant hand that showed 
the highest beta power in the power spectral density and determined the beta-peak frequency as an individual 
parameter to be used for signal  processing11. For patients 1, 8 and 10, the PD-dominant hand was the left, while 
for all others the PD-dominant hand was the right.
Visual neurofeedback. We implemented a custom-written C++-programme to extract an instantaneous 
beta-power estimate from the externalised leads. The programme built on the BrainAmp Software Develop-
ment Kit (Version 002, BrainProducts GmbH, Gilching, Germany), which provided a framework allowing direct 
access to the BrainAmp EEG amplifier through a USB port. Every 40 ms, 200 samples (0.04  s * 5 kHz) per 
channel were bussed through the USB port for processing of the raw signal: First, a bipolar channel was cre-
ated by subtracting one channel from its adjacent channel; second, the raw bipolar lead signal was band-pass 
filtered (Butterworth, 6th order) around the previously determined individual beta peak-frequency ( ± 5 Hz) by 
a rational transfer function; third, the signal was rectified; fourth, the signal from this and the previous 4 blocks 
was averaged (running window average). Finally, the resulting value, representing the instantaneous smoothed 
beta-activity over the preceding 200 ms, was updated at a rate of 25 Hz and used for visual neurofeedback. This 
real-time neurofeedback parameter determined the location of a disc that moved horizontally from lower values 
on the left of the screen to higher values on the right (Fig. 1). The lower limit of the screen was defined as the 
75th percentile beta-power value obtained during 1 min of overt fist opening and closing with the PD-dominant 
hand. The upper limit of the screen was defined as the 75th percentile neurofeedback value during 1 min of star-
ing at the blacked computer screen.
Neurofeedback experiment. The experiment was divided into three parts comprising several 1-min 
blocks: the pre-neurofeedback, the neurofeedback and the transfer part (Supplementary Fig. 1). During the pre-
neurofeedback part, patients had no prior neurofeedback training and were given strategies that might help to 
up- or downregulate beta-activity. It consisted of one block of baseline (staring at the blacked computer screen), 
followed by downregulation, where patients were instructed to imagine fluent movements; and upregulation, 
where patients were instructed to imagine bradykinetic or abruptly ending movements. For the neurofeedback 
(NF) rounds, we provided visual neurofeedback for all blocks except for the baseline blocks. During neuro-
feedback, patients were instructed to voluntarily move the disc on the screen to the right side of the screen 
(upregulation) or to the left of the screen (downregulation) without overt movements (visually controlled by the 
examiner). Patients were allowed to adapt their mental strategies based on success. The following sequence of 
blocks was repeated three times (NF1, NF2 and NF3; except for Patient 1, in which NF2 had to be omitted due 
to time restrictions): baseline, downregulation, upregulation, baseline, upregulation, downregulation. The NF 3 
sequence was repeated for the transfer round, where the computer screen was again turned off (no neurofeed-
back) and patients were instructed to reuse the previously learnt mental strategies for either up- or downregu-
lating beta-activity while staring at the black computer screen and avoiding movements. In total, each patient 
underwent 30 blocks (24 blocks for patient 1) resulting in a raw experimental time of 30 min (24 min for patient 
1). Allowing for short transition periods between the blocks, the total experimental time was usually between 40 
and 50 min. Moreover, we noted the final mental strategies used by the patients to either up- or downregulate 
during the last round of neurofeedback (NF3) for later analysis.
To capture the behavioural effects of neurofeedback, each block during NF3 was immediately followed by 
a period of 15 s, where patients were instructed to alternatingly and completely (i. e. 180° rotations) pro- and 
Figure 1.  Deep brain electrical neurofeedback loop. Deep brain stimulation electrodes (upper left corner) 
implanted into the subthalamic nucleus allowed for brain oscillation measurements. The raw, analogue 
signal was amplified and then digitally band-pass filtered around the individual beta-peak (± 5 Hz), rectified, 
averaged and used to control the position of the blue disc on the monitor (upper right corner). Patients tried 
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supinate their more severely affected hand as fast as possible. We used an inertial measurement unit (IMU) 
mounted on the hand to log the recordings at 200 Hz (ZurichMOVE, https:// www. zuric hmove. com). Two days 
after the initial neurofeedback experiment (i. e. after DBS lead internalisation and thus without neurofeedback), 
we assessed the effect of neurofeedback-learnt mental strategies on motor performance (again in L-DOPA OFF 
and DBS OFF) during a repetition of the transfer round with the pro- and supination motor task following each 
block.
Since the bidirectional neurofeedback design allowed for intra-individual control, differences in the amount 
of beta-oscillations would be solely attributable to the neurofeedback condition, making a separate control group 
superfluous. Moreover, the bidirectional neurofeedback design also controlled for possible eye movement contri-
butions to neuromodulation. The study was single-blinded, i. e. patients were unaware of the neuromodulatory 
effect (beta-upregulation vs. downregulation) of moving the disc to either side.
Post-hoc data analysis and statistics. The raw signal from each electrode site was saved in the Brain-
Amp EEG format and later converted to European Data Format (edf) by BrainVision Analyzer (BrainProducts 
GmbH, Gilching, Germany). The edf was imported into MATLAB (R2018b, The MathWorks Inc., Natick, Mas-
sachusetts, USA) for all further data analyses and statistics. To reconstruct the previously visualised signals, we 
calculated the same bipolar montage from the raw data and filtered using the same algorithms as during the 
real-time programme. The signal from each block was later rectified and averaged. The averaged values obtained 
for the up- or downregulation blocks were then normalised with the values from the preceding baseline block. 
Finally, the normalised values from the same condition of the same block (pre-neurofeedback, NF1, NF2, NF3, 
transfer) were averaged for between condition comparison. Hypothesis testing with two-sided Student’s t-test 
was used to determine whether neurofeedback significantly modulated the instantaneous beta-power. We used 
Wilcoxon’s signed rank test to compare the pre-neurofeedback with the transfer values. Additionally, we used R 
(version 4.0.2)21 and  lme422 to perform linear mixed effects analyses of the relationship between the beta-power 
estimate and the neurofeedback time as well as neurofeedback direction. For all linear mixed effect models, we 
had subject as a random intercept and random slope effect and calculated p-values by likelihood ratio tests with 
the effect in question against the model without the effect in question. In order to assess the effect of neurofeed-
back downregulation time on the beta-power estimate, we tested the full model with the fixed effect of neuro-
feedback time against the model without the fixed effect of neurofeedback time. For effects in the bidirectional 
neurofeedback design, we tested the full model with the fixed effects of neurofeedback time and neurofeedback 
direction against the model without the fixed effect of neurofeedback direction. We correlated the MDS-UPDRS 
III OFF score with the beta-modulatory capacity to assess the relationship between disease burden and the 
ability to modulate pathological oscillations, i. e. the maximum percent difference between the average beta-
power during the baseline rest block (100%) and its subsequent downregulation block during the neurofeedback 
part. The gyroscope data from the IMU was imported into MATLAB. A custom-written script summed the 
three pairwise-orthogonal gyroscope axes up before integration and band-pass filtering between 0.25 and 4 Hz 
 (6th order Butterworth). To examine the motor performance, the pro- and supination segments were visually 
identified for each patient and truncated to the first 12 s (informed decision to avoid the effect of prematurely 
terminated movements). The following metrics were calculated and averaged over repetitions of the same condi-
tion for each individual patient: number of pronosupination cycles (measure of frequency), mean peak angular 
amplitude (measure of movement extent), cumulative angular displacement (measure of total movement extent) 
and mean absolute angular acceleration (measure of the torque generated by the antagonistically acting pro- and 
supinator muscles). We used Wilcoxon’s signed rank test to compare the behavioural metrics after rest versus 
downregulation.
Human participants statement. This research project involving human participants has been approved 
by the local ethics committee (Kantonale Ethikkommission Zürich, board decision on the amendment to KEK-
ZH: 2012-0327), and all patients gave informed written consent prior to inclusion. This research project was 
performed in accordance with the Declaration of Helsinki.
Results
From the 10 patients included in this study, we had to exclude two patients because of intermittent high amplitude 
artefacts in the raw DBS signal, resulting in a total number of 8 patients included for data analysis. The contact 
pairs for the bipolar recording were: 1 × C0–C1, 5 × C1–C2, 1 × C2–C3 and 3 × C9–C10. The mean ( ± standard 
deviation) beta-peak frequency was 20.7 ± 3.3 Hz.
Beta-activity estimate during downregulation vs. rest. We calculated average beta-activity esti-
mates normalised by the beta-activity estimate during the preceding rest block for each individual patient dur-
ing downregulation in pre-NF, all active neurofeedback rounds (NF1, NF2, NF3) and the transfer round (Fig. 2, 
sample recording in Supplementary Fig. 2). The sample mean is below 1 for all but the pre-NF round, indicat-
ing that neurofeedback resulted in reduced beta-activity compared to baseline and was significant (Student’s 
t-test) for NF2 (p = 0.0294), NF3 (p = 0.00092) and the transfer round (p = 0.0134). The beta-activity estimates 
for the transfer round were also significantly lower than during the pre-NF round (Wilcoxon’s signed rank test, 
p = 0.0156). The variance decreased from NF1 up to NF3 and again increased for the transfer round. In the lin-
ear mixed effects model analysis, neurofeedback affected the beta-power estimate ( χ2 = 7.4114, p = 0.006481 ), 
lowering it by about 5.2% (relative to rest) per 2 min of neurofeedback training. More pronounced beta-modu-
lations were achieved by patients with heavier disease burden, as represented by the MDS-UPDRS III OFF score 
(Fig. 3, significant relationship: p = 0.0083; Pearson correlation coefficient: R = 0.84).
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Beta-activity estimate during upregulation vs. downregulation. The average beta-activity estimates 
during upregulation in the pre-NF, NF1, NF2, NF3 and the transfer round were calculated and normalised by the 
beta-activity estimate during downregulation of the same round (Fig. 4). The sample means were above 1 for all 











Figure 2.  Learning to downregulate beta activity with DBS-neurofeedback. Beta-power estimates from all 
patients during downregulation—normalised to the beta-power estimate during each patients’ preceding rest 
block—are shown for the baseline (pre-NF), neurofeedback (NF1, NF2, NF3) and transfer rounds. We indicate 
the cumulative amount of time tcum that patients have spent learning downregulation through neurofeedback 
until the end of that respective round. The group means are represented by the horizontal red lines, the standard 
deviations by the vertical blue lines and the 95% confidence intervals by the red patched areas. We used the two-
sided Student’s t-tests to test for significant beta-reductions compared to the baseline rest (horizontal black line 
at 1). Wilcoxon’s signed rank test was used to compare the dependent samples from the transfer round with their 
pre-NF value. *p < 0.05; ***p < 0.001.
Figure 3.  Relationship between disease burden and beta-modulatory capacity. We correlated the MDS-UPDRS 
III OFF score with the beta-modulatory capacity of each patient (n = 8) and found a significant relationship 
(p = 0.0083) with a positive Pearson correlation coefficient (R = 0.84).
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For NF3, the sample mean was significantly increased in Student’s t-testing (p = 0.0288). In the linear mixed effects 
model analysis, neurofeedback direction was a significant fixed effect ( χ2 = 7.2333, p = 0.007156).
Mental strategies used. The final mental strategies used for up- or downregulating beta-activity were all 
different from the initially suggested ones and highly personalised: Strategies for downregulation ranged from 
imagining running, walking or cycling to just ‘moving the disc to the left’; Strategies for upregulation included 
imagining abrupt movements, difficulties in initiating a movement, freezing, freezing during catching a fish, 
relaxation and trying to ‘move the disc to the right’.
Behavioural outcome after neurofeedback and short-term retention of mental strategy. To 
test for a behavioural effect of neurofeedback-learnt mental downregulation strategies, a set of movement met-
rics for the first 12 s of pronosupination (sample motor behaviour in Supplementary Fig. 3) during the rest con-
dition was compared with the downregulation condition in 7 of the 8 patients (failure of recording in 1 patient). 
The movement frequency was significantly improved (Wilcoxon’s signed rank test, p = 0.0312) after downregula-
tion (Fig. 5A left). To test for a bias towards smaller movement amplitudes, we calculated the mean peak angular 
amplitude, which was slightly and non-significantly reduced (Fig. 5B left). The cumulative angular displacement, 
a combination of the movement frequency and the mean peak angular amplitude, still favoured the downregula-
tion condition (Fig. 5C left). Furthermore, the mean angular acceleration was significantly increased after down-
regulation as compared to the rest condition (Wilcoxon’s signed rank test, p = 0.0469), indicating a significantly 
higher mean torque generated after downregulation (Fig. 5D left). We also examined the motor performance 
after application of neurofeedback-learnt and retained mental strategies in all 8 patients after 2 days, when DBS 
leads had already been internalised and neurofeedback could no longer be provided, and found a similar pattern 
(Fig. 5; Wilcoxon’s signed rank test for the number of pronosupination cycles, p = 0.0156).
Discussion
Many studies have provided evidence for a mutual interaction between beta-oscillatory activity in the STN and 
motor symptoms in PD. Inspired by real-time fMRI studies providing proof-of-principle for endogenous modu-
lation of deep brain networks (although cumbersome and not transferable into everyday life), we investigated a 
novel neurofeedback technique using DBS electrodes implanted in the STN. Using this approach, we provided 
Figure 4.  Learning bidirectional neurofeedback. Beta-power estimates from all patients during upregulation—
normalised to the beta-power estimate during each patients’ downregulation condition—for the Pre-NF, NF1, 
NF2, NF3 and Transfer rounds show increasing beta activity upon neurofeedback aided upregulation. We 
indicate the cumulative amount of time tcum that patients spent learning upregulation through neurofeedback 
until the end of that respective round. The means are represented by the horizontal red lines, the standard 
deviations by the vertical blue lines and the 95% confidence intervals by the red patched areas. We used two-
sided Student’s t-testing to determine significant beta-increases compared to the downregulation condition 
(horizontal black line at 1). *p < 0.05.
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real-time direct visual neurofeedback of subcortical beta-power in the form of a disc that moved horizontally 
on a screen, thereby empowering patients to control their own pathological deep brain oscillations. The core 
findings of this study were that deep brain electrode-guided neurofeedback allows PD patients to gain control 
over subthalamic beta-oscillations, that this control is gradually improved with neurofeedback training and has 
a positive effect on motor performance. Furthermore, our findings suggest that neurofeedback-learnt strategies 
can be retained in the immediate and short-term and that the associated beta-power reduction has a beneficial 
effect on motor performance observed 2 days after neurofeedback-learning.
Deep brain electrical neurofeedback quickly enables control over deep brain activity. Here, we 
demonstrate that real-time modulation of beta-activity is possible, even within as little as 4 min of downregula-
tion training (p = 0.0294) and 6 min of upregulation training (p = 0.0288). This minimal-latency, endogenous 
access to deep brain activity greatly outperforms rtfMRI neurofeedback studies, where the control over the 
BOLD signal requires at least 30 min of training. In comparison to EEG neurofeedback studies, that require 
multiple sessions for controlling cortical  activity23, DBS neurofeedback seems to provide faster and more reliable 
strategy development for the participants. This striking difference could be explained by local measurement of 
neuronal activity directly at the target deep brain area of basal ganglia-cortical  loops11,24. More so, electrical neu-
rofeedback of the STN seems to be readily achievable, as all patients in our study managed to reduce pathological 
oscillations after only 6 min of downregulation training. Importantly, given our bidirectional neurofeedback 
design (within-subject control strategy, i. e. all patients serve as their own control), the modulatory effect can be 
attributed to the learning process of neurofeedback.
Control over deep brain activity rapidly improves with further neurofeedback-training. We 
demonstrate that lengthening the exposure to visual neurofeedback results in a better control over pathological 
beta-oscillations, as shown in a stronger and more significant reduction of beta-oscillations by the end of NF 3 
(Fig. 2). Since one individual achieved a beta-reduction of ∼ 35% and we did not see any plateau effect in the 
learning curve by the end of 8 min of downregulation training, we hypothesise that stronger beta-reductions 
could yet be achieved through longer training sessions. Upregulation through neurofeedback was less effective 
(not-significant compared to rest), which might be due to the reason that beta-activity during rest is known to 
be pathologically increased in PD and resting activity was used as baseline condition. Nevertheless, upregulation 
through neurofeedback was an important within-subject control condition to prove bidirectional neurofeedback 
control, where factors such as concentration, visual feedback and eye movements were nearly identical and could 
thus be excluded as potential confounders. Of note, the initial strategy to downregulate (pre-NF) on average 
lead to a higher beta-activity as compared to the resting state. This suggests that controlling deep-brain activity 
without neurofeedback does not seem to be intuitive. Moreover, neurofeedback helps in selecting and optimising 
mental strategies, as all patients reported a different strategy by NF3.
Figure 5.  Behavioural output metrics during the first 12 s of pronosupination after downregulation during 
NF3 and short-term (2 days) mental strategy transfer. (A) The pronosupination frequency (proportional to the 
number of cycles during the first 12 s of pronosupination) was significantly increased after downregulation as 
compared to rest (p = 0.0312 and p = 0.0156 during NF3 and 2 d mental strategy transfer, respectively) while 
(B) the mean peak angular amplitude was only slightly and non-significantly decreased. (C) The cumulative 
angular displacement (i. e. degrees travelled) was generally higher after downregulation as compared to rest. The 
grey rectangle highlights the mutual dependence between the three variables in (A–C), i. e. frequency * mean 
peak angular amplitude = cumulative angular displacement. (D) The torque generated by the antagonistically 
acting pro- and supinator muscles was estimated through the mean absolute angular acceleration, which 
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After training, beta-oscillations can be reduced without neurofeedback. Even in the absence 
of visual neurofeedback and after only 6 min of effective downregulation learning, PD patients still managed to 
significantly reduce subthalamic beta-activity using their novel neurofeedback-learnt strategies. Performance 
during this condition (transfer run) was also significantly better than before neurofeedback learning (pre-neu-
rofeedback run) as evaluated by the Wilcoxon’s signed rank test. We observed an increase of variance in the 
amount of beta power downregulation from NF 3 to the transfer round. We believe that this difference is due to 
the fact that visual neurofeedback is no longer provided and that some subjects manage to obtain even stronger 
neuromodulation (possibly because they could concentrate better on the learned mental strategy) while some 
subjects perform worse, possibly due to the missing visual cues. Overall, we observed a slightly decreased down-
regulation ability without visual neurofeedback. Thus, continuous neurofeedback, besides allowing for further 
learning, also allows for a more efficient control over deep brain activity.
Motor performance improvements. The analysis of motor performance after employing neurofeed-
back-learnt strategies revealed promising results in behavioural outcome metrics. Immediately after neurofeed-
back-guided beta downregulation, the pronosupination frequency was significantly higher while movement 
amplitude was only slightly and non-significantly reduced, still resulting in a larger cumulative angular displace-
ment. Furthermore, the mean torque generated, estimated by the mean absolute angular acceleration and as such 
a measure for alternating activation of pro- and supinator muscles of the forearm, was significantly increased 
after downregulation. A similar pattern was observed 2 days later, suggesting that neurofeedback-learnt mental 
strategies are retained in the short-term and motor performance improvements can be achieved without active 
neurofeedback. A limitation of this study is that we only included a single motor task instead of adding also a 
second task, for instance from the MDS-UPDRS. As such, we also only focused determined the effect of neu-
rofeedback on bradykinesia and were blind to effects on for instance tremor or non-motor symptoms. Further-
more, we assessed the effect of neurofeedback-learnt mental strategies on a single time point (i. e. 2 days) after 
neurofeedback learning since at that point we expected all patients to still be at the hospital and not at a remote 
rehabilitation clinic and as we expected a better comparability of behavioural performance (a long-term time 
point might have shown overall better baseline motor performance).
Implications for Parkinson’s disease and beyond. We showed that self-control over pathological deep 
brain oscillations can be achieved through DBS-neurofeedback, which in turn improved motor performance in 
our cohort. Given the strongly fluctuating nature of PD, neurofeedback-learnt strategies to control pathologi-
cal deep brain oscillations could help patients cope with situations of transient symptomatic exacerbations: PD 
patients could apply neurofeedback-learnt strategies to overcome sudden symptomatic exacerbations. Interest-
ingly, the beta-modulatory capacity correlates with disease burden (Fig. 3), possibly reflecting that a pronounced 
pathological background beta-activity is required for stronger beta-modulation. This finding further motivates 
the use of deep-brain neurofeedback especially during symptom exacerbations or in severely affected patients. 
Although our results have to be interpreted cautiously, we provide evidence that endogenous modulation of 
pathological beta activity may result in improved motor control and thus complement dopaminergic treatment 
or brain stimulation. Thus, neurofeedback could also result in a reduced overall exposure to medication and 
brain stimulation, thereby combating the development of tolerance as well as potentially having a halting or 
reversing effect on the natural progression of PD through neuroplasticity by repeated self-activation of neu-
ronal circuits. Along this line, a recent study was able to show that neurofeedback of deep brain beta-activity 
induced changes in the resting oscillatory activity before versus after neurofeedback in the respective direction 
of  neurofeedback17.
These effects can be expected to be more pronounced when longer neurofeedback training is provided using 
DBS systems that wirelessly transmit signals to an external  device25 for real-time neurofeedback. Finally, neuro-
feedback can reincorporate PD patients into the treatment loop: Compared with current DBS strategies, where 
PD patients are mere bystanders with little to no control over their burden (and therapy), PD patients could exert 
neurofeedback-learnt control over pathological deep brain activity in order to reduce stimulation and medica-
tion load while simultaneously increasing motor performance through endogenous beta reduction. As DBS 
has recently also been explored for neurological diseases like epilepsy, obsessive–compulsive disorder, anxiety, 
depression and attention deficit/hyperactivity disorder, deep brain electrode-guided neurofeedback could be 
simultaneously studied as a complementing treatment strategy. We showed that not only unidirectional but also 
bidirectional neurofeedback control can be achieved within a matter of minutes, thus making neurofeedback 
interesting for cases where a stabilisation or reinforcement of oscillatory patterns is beneficial.
Outlook. The full extent to which voluntary self-regulation of deep brain oscillatory activity is possible and 
improves motor outcome yet remains to be unveiled as our study was limited by a short intervention time. We 
believe that Parkinsonian motor symptoms can be improved by providing longer neurofeedback intervention 
times, ideally chronic neurofeedback in the context of an implantable device. Improved motor control promoted 
through these optimised neurofeedback interventions will need to be selectively verified in activities of daily liv-
ing. Furthermore, future studies should investigate combinatorial approaches and assess whether neurofeedback 
can reduce the dependence on dopaminergic medication or electrical stimulation, thereby possibly reducing 
medication side effects or prolonging battery life, respectively.
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Conclusion
This intracranial electrophysiological human study provides the first evidence of patients rapidly gaining real-
time control over ongoing deep-brain oscillatory activity through visual neurofeedback. Moreover, neurofeed-
back-learnt control improves with training duration, is retained in the immediate and short-term even in the 
absence of neurofeedback and improves motor performance. This novel approach could enable PD patients to 
regain control over aberrant deep brain signalling as well as result in better motor control and, thus, complement 
current treatment approaches.
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